Medeva/SmithKline Vaccine Alliance
Medeva and SmithKline Beecham have signed an agreement to form an alliance in the development, manufacture and marketing of vaccines for various diseases.
Medeva, which acquired the human vaccine rights to the 69kDa acellular pertussis vaccine component as part of its acquisition of Wellcome's human vaccine business in 1991, has licensed the rights to 69kDa to SmithKline Beecham. The protein is expected to be a key component in a new-generation pertussis vaccine and is contained in the vaccine SmithKline will be launching in Europe and the USA. Royalties will be paid to Medeva by SmithKline and by sublicensees, subject to minimum payments.
The companies have further agreed to codevelop and comarket in the UK new combined vaccines containing diphtheria-tetanus/pertussis and Hemophilus influenzae type B, and other nonspecified vaccines produced by the firms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze